Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab

Linden, Michael A.; Bachanová, Veronika; Sachs, Zohar; Young, Jo Anne H.; Singleton, Timothy P.; Üstün, Celalettin

doi:10.3109/10428194.2012.691484

Search citation statements

Order By: Relevance

Paper Sections

Select...

Clinical Studies In Dlbcl1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another interesting indication of ofatumumab was the use of rituximab in patients with allergy [36]. However, with the occurrence of third-generation mAbs, this indication will disappear.…”

Section: Clinical Studies In Dlbclmentioning

confidence: 99%

Ofatumumab in the treatment of non-Hodgkin’s lymphomas

Karlin

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…Another interesting indication of ofatumumab was the use of rituximab in patients with allergy [36]. However, with the occurrence of third-generation mAbs, this indication will disappear.…”

Section: Clinical Studies In Dlbclmentioning

confidence: 99%

Ofatumumab in the treatment of non-Hodgkin’s lymphomas

Karlin

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

Ofatumumab for Post-Transplant Lymphoproliferative Disorder

Seshadri

Crane

Gergis

2022

Hematology/Oncology and Stem Cell Therapy

View full text Add to dashboard Cite

Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with Epstein–Barr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of ritux- imab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.

show abstract

Allogeneic HCT Should Be the Referred Therapy for Richter's Transformation

Khouri

2024

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab

Cited by 4 publications

References 9 publications

Ofatumumab in the treatment of non-Hodgkin’s lymphomas

Ofatumumab in the treatment of non-Hodgkin’s lymphomas

Ofatumumab for Post-Transplant Lymphoproliferative Disorder

Allogeneic HCT Should Be the Referred Therapy for Richter's Transformation

Contact Info

Product

Resources

About